Led by $230m acquisition of M.I.Tech, Asia-Pacific’s medical devices industry saw a drop of 26.05% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 22 cross border deals worth $689.9m were announced for the region during Q2 2022, against the last four-quarter average of 29.75 deals.

Of all the deal types, venture financing saw most activity in Q2 2022 with 13 deals, representing a 59.1% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In second place was M&A with seven deals, followed by private equity deals with two transactions, respectively capturing a 31.8% and 9.1% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $251.77m, while M&A and private equity deals totalled $230m and $208.13m, respectively.

Asia-Pacific medical devices industry cross border deals in Q2 2022: Top deals

The top five medical devices cross border deals accounted for an 82.5% share of the overall value during Q2 2022.

The combined value of the top five cross border deals stood at $569.13m, against the overall value of $689.9m recorded for the quarter.

1) Boston Scientific $230m acquisition deal for 64% stake in M.I.Tech

2) The $140.13m private equity of Genea by Liverpool Partners

3) Globis Capital Partners &,Incubate Fund,SoftBank Vision Fund 2 and World Innovation Lab (WiL fund) $70m venture financing deal with AI Medical Service

4) The $68m private equity of Accumax Lab Technology by Creador Sdn and India Life Sciences Fund III

5) Alkemi Venture Partners,Chiratae Ventures,HealthQuad,LC Nueva AIF,LeapFrog Investments,Schroders and Spark Growth Ventures $61m venture financing deal with Redcliffe Lifetech